Lund, Sweden, June 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, at 8:45 AM EDT on Thursday, June 4, 2026. Read more…
Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development Heidelberg, Germany – 2 June 2026 – FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate […]
Lund, Sweden, 29 May 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today are proud to announce that Renée Aguiar-Lucander, CEO, Hansa Biopharma has been named one of Sweden’s Most Influential Business Women of 2026 by Dagens industri. This nomination recognizes leaders with significant influence over the development, competitiveness and future of Swedish business. The […]
Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following transplantation Investigator-sponsored Phase 1 trial underway at the Ajmera Transplant Centre, University Health Network (UHN), Toronto, a world-renowned transplant center, conducted by Professor Atul Humar […]
Commercial-scale production of Kaleido consumables begins at contract manufacturer Phillips Medisize Manufacturing capacity more than triples, with initial capacity to support over 17,000 users Volume manufacturing drives gross margin expansion Utrecht, the Netherlands — May 28, 2026 ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced that commercial‑scale production […]
